The latest product monograph supporting the biosimilarity of NYVEPRIA. Includes information on the indication, dosing, study data (both analytical and clinical), and safety, as well as reimbursement and access.
A helpful resource for your practice, covering how to order NYVEPRIA as well as potential cost savings.
Quick reference highlighting relevant billing and coding information for NYVEPRIA, including HCPCS, NDC, CPT, and ICD-10-CM codes.
*Biosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product, known as a reference product, and that there are no clinically meaningful differences between the biosimilar and the reference product.1-6
1. NIVESTYM [prescribing information]. New York, NY: Pfizer Inc.; November 2021. 2. NYVEPRIA [prescribing information]. New York, NY: Pfizer Inc.; October 2021. 3. RETACRIT [prescribing information]. New York, NY: Pfizer Inc.; August 2020. 4. RUXIENCE [prescribing information]. New York, NY: Pfizer Inc.; November 2021. 5. TRAZIMERA [prescribing information]. New York, NY: Pfizer Inc.; November 2020. 6. ZIRABEV [prescribing information]. New York, NY: Pfizer Inc.; May 2021.
Avastin and Herceptin are registered trademarks of Genentech, Inc. Epogen, Neulasta, and Neupogen are registered trademarks of Amgen Inc. Procrit is a registered trademark of Janssen Products, LP. Rituxan is a registered trademark of Biogen, Inc.
NYVEPRIA is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs associated with a clinically significant incidence of febrile neutropenia.
Limitations of Use
NYVEPRIA is not indicated for the mobilization of peripheral blood progenitor cells for hematopoietic stem cell transplantation.